The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...

We recently published 10 Big Names Leaving Wall Street Behind; 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one ...

Astellas Pharma presented new results from cohort 9 of the EV-202 trial at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany, from 17 to 21 October. Conducted in ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

Merck (MRK) is back in focus after a trio of recent developments, including an upcoming J.P. Morgan Healthcare Conference fireside chat, encouraging KEYTRUDA ovarian cancer trial results, and a ...